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ABSTRACT 
Fast dissolving/disintegrating films/tablets have received ever-increasing demand during the last decade, and the field has become a rapidly 
growing area in the pharmaceutical area. Particularly the fast dissolving drug delivery systems formulated with natural polymers have more 
demand because natural materials like gums and mucilages have been extensively used in the field of drug delivery for their easy availability, 
ease administration, non toxicity, non irritant nature etc. Atenolol is β1-selective adrenergic blocking agent and widely used in the treatment of 
hypertension and angina pectoris. It has a bioavailability of 40-50%. The main objective of the study was to formulate taste masked oral fast 
disintegrating films of Atenolol to achieve a better dissolution rate by improving the bioavailability of the drug and providing quick onset of 
action thereby enhancing patient compliance. Oral FDF prepared by solvent casting method using water and 95% ethanol as solvents and HPMC 
as film forming polymer. PEG 400 was the selected plasticizers, Natural and synthetic superdisintegrants such as croscarmellose sodium (CCS), 
sodium starch glycolate (SSG) and fenugreek mucilage alone and also in combinations was incorporated to achieve quick onset of action, is to 
increase the water uptake with in shortest wetting time and there by decrease the disintegration time. The prepared films were evaluated for 
the drug content, weight variation, film thickness, disintegration time, folding endurance, percentage of moisture content and in vitro 
dissolution studies and taste mask studies on healthy human volunteers. Among all, the formulation F5 was found to be best fo rmulation which 
releases 98.89% of the drug within 15 min and disintegration time is 59 sec. which was significantly high when compared to other formulation. 
The data obtained from in-vitro release were fitted into the various kinetic models such as Zero Order, Higuchi, First Order and Korsmeyer –
Peppas Model in order to determine the mechanism of drug release. When the regression coefficient values compared, it was observed that ‘r’ 
values of formulation F5 was maximum i.e 0.890 hence indicating drug release from formulations was found to follow zero order  drug release 
kinetics. 
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INTRODUCTION 
Presently, there is a high level of interest in the use of the 
oral cavity as a portal for drug entry to the systemic 
circulation. As a site for drug delivery, the oral cavity offers 
advantages over the conventional GIT, parenteral and 
alternative routes of drug administration. Oral thin films are 
postage stamp-sized rectangular shape polymeric films 
which instantaneously disintegrate and dissolve within 
seconds when placed on the tongue. Oral films are preferred 
by patients suffering from dysphasia, motion sickness, 
repeated emesis and mental disorders since they are unable 
to swallow large amounts of water. The advantages of 
convenient dosing and portability of oral strips have led to a 
wide applicability of this dosage form in pediatric as well as 
geriatric patients. The advantages of sublingual delivery of 
drugs via oral films include larger surface area, enhanced 
safety, high precision during dose administration compared 
to liquid forms, high levels of patient compliance, and 
quicker relief 1. Additionally, other oral formulations can be 
subject to poor absorption, or delayed onset due to 
degradation by the gastrointestinal tract, as well as first pass 
metabolism by the liver. Also, although oral disintegrating 
tablets disintegrate quickly, their disintegrated materials 
remain insoluble until swallowing. Buccal or sublingual 
delivery through thin films therefore provides a way to 
circumvent swallowing through rapid dissolution in the oral 
cavity, thereby causing quick onsets of action at a lower 
dosage. As the oral film releases the drug instantly, this 
dosage form can be formulated for to treat diseases, such as 
pain, allergies, sleep disturbances, anxiety and gastric 
problems, which require a fast onset of action2. Chemically 
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Atenolol is 4-(2-Hydroxy-3-[(1-methyl ethyl) amino] 
propoxy) benzene acetamide3 β1-blocker is prescribed 
widely in diverse cardiovascular diseases, eg, hypertension, 
angina pectoris, arrhythmias and myocardial infarction. The 
drug is also frequently indicated in the prophylactic 
treatment of migraine4. Administration of conventional 
tablets of Atenolol has been reported to exhibit fluctuation in 
the plasma drug levels, resulting either in manifestation of 
side effects or reduction in drug concentration at the 
receptor site5. Oral bioavailability of Atenolol is around 50% 
and having half life 6 to 7 hrs6. For poorly soluble orally 
administered drugs the rate of absorption is often controlled 
by the rate of dissolution. The rate of dissolution can be 
increased by increasing the surface area of available drug by 
various methods (micronization, complexation, solid 
dispersion, etc). Majority of investigations on natural 
polymers in drug delivery systems are centered on 
polysaccharides and proteins7. Number of natural, synthetic 
and semi synthetic polymer materials is used in the various 
drug delivery systems8, but mucilage of natural origin is 
more preferred over synthetic and semi synthetic substances 
because they are comparatively cheap, abundantly available, 
non-toxic and non-irritating in nature9. In this study, natural 
substances like fenugreek seed mucilage was used as 
superdisintegrants in the formulation of film. 
MATERIALS AND METHODS  
Materials 
Atenolol was obtained as gift sample from Natco Pharma, 
Hyderabad, India. HPMC was procured from Qualikems fine 
chem. Pvt Ltd Vadodhara. PEG400, sodium starch glycolate, 
croscarmellose sodium, aspartame and SLS was obtained 
from S.D fine chemicals limited, Mumbai. Fenugreek seeds 
were obtained from local market of Bhopal.  All the chemicals 
used in this work were of analytical grade. 
Formulation Development 
Extraction and isolation of fenugreek mucilage 
The clean, dry fenugreek seeds were grounded under mild 
conditions using a laboratory mixer. The grounded seeds 
were then sieved to remove the germ which possesses the 
lowest hardness. The remaining part was soaked overnight 
in water, to allow the gum to swell. The swelled gum was 
separated from the other components of the seeds via 
filtration through a muslin cloth. The separated gum was 
either used as it is, i.e. in the viscous form or precipitated 
using commercial ethyl alcohol, dried and finally grinded to 
fine powder 10. 
Formulation development of oral film of Atenolol 
Drug (Atenolol) containing FDF were fabricated by the 
solvent casting method. The optimized amount of HPMC was 
dissolved in 5ml of water and stirrer continuously for 1 hour, 
optimized amount of Plasticizer were dissolved in 95% 
ethanol and then added to the polymeric solution, the 
optimized amount of drug was dissolved in 2ml of water and 
kept on sonication for proper dispersion. Polymeric solution 
was stirred for 30 min using magnetic stirrer and was kept in 
undisturbed condition till the entrapped air bubbles were 
removed. The aqueous solution was casted in a glass moulds 
having 2.5 x 2.5 cm*12 films area and was dried at controlled 
room temperature (25°-30°C, 45%RH) as well as at 
increased temperature (microwave oven). The film took 
approximately 48 hr to dry at controlled room temperature. 
The dried film was carefully removed from the glass plates 
and was cut into size required for testing. The films were 
stored in air tight plastic bags till further use. The 
compositions of the formulations were shown in table 1. 
 
Table 1 Formulation of Atenolol oral fast disintegrating films 
Name of ingredients (mg) 
(mg for 12 strips) 
F1 F2 F3 F4 F5 F6 
Atenolol 300 300 300 300 300 300 
HPMC 250 500 750 250 500 750 
PEG-400 150 150 150 150 150 150 
SSG 150 200 250 - - - 
CCS - - - 150 200 250 
SLS 10 - - 10 - - 
Fenugreek mucilage 4 4 4 6 6 6 
Citric acid 100 100 100 100 100 100 
Aspartame 10 10 10 10 10 10 
Glycerin - - - - - - 
DM water  qs to (ml) - - - - - - 
 
Dose calculations 
 Width of the plate = 5cm 
 Length of the plate = 12cm 
 No. of 2.5 x 2.5 cm2 films present whole plate = 12 
 Each film contains 25 mg of drug. 
 12 no. of films contains mg of drug? = 25×12 = 300mg 
 The amount of drug added in each plate was 
approximately equal to 300mg. 
Evaluation of mucilage 
The separated mucilage was evaluated for swelling index, 
loss on drying, density, compressibility index and angle of 
repose. 
 
Determination of swelling index 
The swelling index is the volume in ml occupied by 1g of 
drug; including any adhering mucilage after it has been 
swollen in an aqueous liquid for 4h .The swelling index of 
fenugreek mucilage powder, was determined according to 
the (Kumar et al 2014)11. One gram of mucilage powder was 
taken in a 25 ml ground glass stoppered cylinder graduated 
over a height of 120 to 130 mm in 0.5 divisions. To this 25 
ml of water was added and this was shaken vigorously every 
10 m for 1h and then allowed to stand for 24 h. The volume 
occupied by mucilage was measured. The Swelling index was 
calculated from the mean of three determinations. 
Swelling Index % (SI) = (W2 – W1/W1) x 100 ---------- (1) 
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W1= Initial Volume in ml, W2= Final Volume in ml    
Loss on drying 
Loss on drying is directly measured by IR moisture balance 
(Labgo Infrared Moisture Balance). Firstly calibrated the 
instrument by knob then taken 5.000 gm sample (powder) 
and set the temp at 100°C to 105°C for 15 minutes and 
constant reading set the knob and check % moisture. 
Evaluation of prepared Film12-15  
The formulations were evaluated by the following tests. 
Thickness 
Randomly 10 films were selected and thickness was 
measured using vernier calliper at three different places. 
Weight variation  
For each formulation, three randomly selected patches were 
used. For weight variation test, 10 films from each batch 
were weighed individually by digital electronic balance and 
the average weight was calculated. 
Folding endurance 
This was determined by repeatedly folding one film at the 
same place until it broke. The number of times the film could 
be folded at the same place without breaking cracking gave 
the value of folding endurance.  
Percentage of moisture content 
The films were weighed individually and kept in desiccators 
containing activated silica at room temperature for 24 hrs. 
Individual films were weighed repeatedly until they showed 
a constant weight. The percentage of moisture content was 
calculated as the difference between initial and final weight 
with respect to final weight.  
Drug content analysis 
The patches (n = 3) of specified area were taken into a 10 ml 
volumetric flask and dissolved in methanol and volume was 
made up with 10 ml methanol. Subsequent dilutions were 
made and analyzed by UV spectrophotometer at 282nm.  
Disintegrating time 
The most important criteria of present work are to that 
dosage form should be dissolved within few seconds. The 
incorporation of super disintegrating agent to minimizes the 
disintegrating time. Three super disintegrating agent were 
selected for this work. The film of (4.15cm2) size (unit dose) 
was placed on a petridish containing 10 ml of distilled water. 
The time required for the film to break was noted as cursive 
in vitro disintegration time. 
In vitro dissolution study  
The in vitro dissolution test was performed using the 
USPXXX dissolution apparatus II (Paddle with sinker). The 
dissolution studies were carried out at 37±0.5° C; with 
stirring speed of 50 rpm in 900 ml phosphate buffer (pH 
6.8). Film size required for dose delivery (2.5×2.5 cm2) was 
used. Five ml aliquot of dissolution media was collected at 
time intervals of 1, 2, 5, 10 and 15 minutes and replaced 
with equal volumes of phosphate buffer (pH 6.8). The 
collected samples were filtered through 0.45 μm membrane 
filter and the concentration of the dissolved Atenolol was 
determined using UV-Visible spectrophotometer at 282nm. 
The results were presented as an average of three such 
concentrations. 
Stability studies 
Stability studies were carried out with optimized 
formulation which was stored for a period of one, two and 
three months at 40±2oC temperature and 75±5% relative 
humidity for a period 3 months. The % Assay of formulation 
was determined by U.V. spectrophotometer using calibration 
curve method. The % assay of film was found to slightly 
decrease at higher temperature.  
RESULTS AND DISCUSSION 
The percentage yield of mucilage was found 46.0%. The loss 
on drying and swelling index of isolated mucilage was found 
to be 73.867±1.338% and 162.478±1.022% respectively.  λ 
max of Atenolol was found to be 282 nm in 6.2 pH phosphate 
buffer solution by using U.V. spectrophotometer (Labindia-
3000+). The general appearance, weight variation and 
thickness of all the films were within acceptable limits table 
2.
 
Table 2 Result of general appearance, thickness and weight variation  
Formulation code General Appearance Thickness* (µm) Weight* (mg) 
F1 Translucent 88±5 110±2 
F2 Translucent 90±4 114±3 
F3 Translucent 92±8 115±4 
F4 Translucent 95±5 120±2 
F5 Translucent 98±4 123±4 
F6 Translucent 90±5 125±1 
*Average of three determinations (n=3) 
The results for folding endurance, disintegrating time, tensile 
strength, % of moisture content and % Assay were shown in 
table 3. Tensile strength value of optimized formulation (F5) 
was 0.556±0.056kg/cm2 and percent Assay 99.32±0.32 %. 
The folding endurance of the optimized oral fast 
disintegrating formulation (F5) was 168±3. The assay values 
of all the formulations were ranging from 96.65±0.21 to 
99.32±0.32%. The disintegration time was ranging between 
50±5 to 120±4 sec. The final formulation shows better drug 
release (98.89%) compared to other formulation within 15 
m (Table 4). The cumulative percentage (%) drug release 
profile and the assay of the F5 formulation films indicates 
that the drug remain stable under the ASC without any 
significant change in its release profile and the drug content. 
From the stability studies it was clearly observed that the 
drug showed good stability after subjecting to accelerated 
stress conditions and the polymers shown significantly 
compatibility with the drug. The in vitro drug release data of 
the formulation was subjected to goodness of fit test by 
linear regression analysis according to zero order and first 
order kinetic equation and Korsmeyer’s models in order to 
determine the mechanism of drug release. When the 
regression coefficient values compared, it was observed that 
‘r’ values of formulation was maximum i.e 0.890 hence 
indicating drug release from formulations was found to 
follow zero order drug release kinetics table 5 and fig 1&2. 
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Table 3 Result of folding endurance, disintegrating time, tensile strength, moisture content & % assay  
F. code Folding endurance 
(Times) 
Disintegrating 
time (Sec.) 
Tensile strength*  
kg/cm2 
% of Moisture 
content* 
% Assay* 
F1 125±4 120±4 0.852±0.025 2.95±0.04 98.85±0.23 
F2 130±3 89±5 0.785±0.032 2.45±0.05 97.78±0.45 
F3 128±4 80±2 0.658±0.014 2.65±0.06 96.65±0.21 
F4 135±2 86±4 0.458±0.023 2.32±0.04 98.74±0.28 
F5 168±3 59±3 0.556±0.056 1.45±0.02 99.32±0.32 
F6 149±4 50±5 0.658±0.074 2.85±0.07 98.58±0.41 
*Average of three determinations (n=3) 
Table 4 Results of In-Vitro release study of optimized 
formulation F5 
S. No. Time (Min.) Cum % Drug release 
1. 1 22.36 
2. 2 48.89 
3. 5 65.58 
4. 10 79.98 
5. 15 98.89 
 
 
Figure 1 Zero order release kinetics of optimized 
formulation F5 
 
Figure 2 First order release kinetics of optimized 
formulation F5 
Table 5 Kinetics data of Optimized Formulation F5 
Formulation Regression 
Coefficient 
Zero order First 
order 
F5 r2 0.890 0.880 
 
CONCLUSION 
In the present study the superdisintegrant property of 
Fenugreek seed mucilage has been explored. Extensive 
swelling, porosity and wicking action of the natural material 
in the FDF formulation were found to be contributing its 
superdisintegrant action. FDF of Atenolol was formulated 
with an aim to improve the versatility, convenience, patient 
compliance leading to an enhanced approach for the 
administration of drug to the pediatrics and geriatrics. Also 
suitable for clinical use in the treatment of hypertension 
where a quicker onset of action with the convenience of 
administration. Further taste masking studies proved that 
the FDF produced faster onset of action and resulted in 
complete masking of metallic taste of Atenolol and hence, 
improved the patient compliance. Based on results, 
formulation F5 was the best one from prepared FDF 
formulations. Stability studies were carried out for 3 months 
and all the formulations were found to be stable after 2 
months. 
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